Business
Exclusive worldwide option over megakaryocyte IP
Exclusive worldwide option over megakaryocyte IP.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 5663Q Angle PLC 13 September 2017 \n\n\n\n\n\nFor immediate release\n\n\n 13 September 2017\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nEXCLUSIVE WORLDWIDE OPTION OVER MEGAKARYOCYTE INTELLECTUAL PROPERTY \n \nANGLE signs option over patent applications filed on Barts Cancer Institute's discovery of megakaryocytes' role in cancer\n \nMegakaryocytes' presence in prostate cancer linked to patient survival; such cells potentially have role in all cancer types\n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that it has signed an option agreement with Queen Mary University of London (QMUL) for an exclusive worldwide licence over the use of its megakaryocyte intellectual property.\n \nAs announced on 15 June 2017, QMUL published research in Clinical Cancer Research using ANGLE's Parsortix system showing that the number of megakaryocyte cells in the blood of prostate cancer patients correlates closely with increased patient survival. This is the first time the presence of these cells in patient blood has been shown to be connected to cancer prognosis. \n \nInvestigation of megakaryocytes in patient blood opens up the potential for a whole new area for cancer diagnostics and, at present, ANGLE's patented Parsortix system is the only system that has demonstrated the capability of harvesting megakaryocytes. \n \nQMUL have filed two patent applications in relation to these findings which are being prosecuted worldwide. ANGLE has signed a two year option to an exclusive worldwide licence to these patents covering any medical therapeutic, diagnostic, or prophylactic application. ANGLE has agreed to cover the costs of prosecution. \n \nThrough this deal, ANGLE now has intellectual property protection over the upstream cell capture technology (its existing Parsortix IP) and the downstream megakaryocyte analysis technology (via the option agreement announced today). Megakaryocyte analysis may provide medical insight in multiple cancer types and Barts Cancer Institute, which is part of QMUL, is investigating other cancer types to substantiate this. \n \nThe Parsortix system has been shown to be capable of harvesting for analysis not only mesenchymal CTCs, which are linked to ...